Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Suvorexant (Belsomra) on Sympathetic Neural Activity and Baroreflex Function in Patients With Chronic Insomnia
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Pharmacodynamics
- 05 Oct 2021 Planned End Date changed from 1 Dec 2022 to 1 Apr 2023.
- 05 Oct 2021 Planned primary completion date changed from 1 Aug 2022 to 1 Dec 2022.
- 28 Oct 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.